It has also been shown that the oxidative metabolism of tumor cells is a barrier to PD‐1 immunotherapy, and that mitochondrial oxidative phosphorylation is not only not impaired but more activated in several cancers (pancreatic adenocarcinoma, melanoma, and leukemia).35 Here, PDCD1 is linked to melanoma.